Molecular Biosystems appoints Jerry T. Jackson to board of directors

Business Wire, Dec 18, 1996

SAN DIEGO--(BUSINESS WIRE)--Dec. 18, 1996--Molecular Biosystems Inc. (NYSE:MB) (MBI) Wednesday announced that Jerry T. Jackson, former executive vice president of Merck & Co. Inc., has been appointed to the company's board of directors.

Jackson brings 30 years of worldwide marketing, sales and product launch experience to MBI.

From 1965 to 1995, Jackson served in several key senior management positions in sales, marketing and planning at Merck & Co. Inc. The various positions included senior vice president of Worldwide Human Health Marketing, president of Merck Sharp & Dohme International and president of Merck's Worldwide Human Health Division. Until his retirement in 1995, he served as executive vice president of Merck & Co.

Jackson is the second appointment to MBI's board of directors this year. In June, David W. Barry, M.D., chairman and chief executive officer of Triangle Pharmaceuticals and former president of Wellcome Research Laboratories joined MBI's board. Their combined expertise in worldwide marketing, strategic planning, R&D and regulatory affairs will assist the company in the objective of becoming the global leader in ultrasound imaging agents.

Commenting on the appointment, MBI's chairman and chief executive officer, Kenneth J. Widder, M.D., stated: "We are pleased that Mr. Jackson has chosen to join our board and we welcome his vast knowledge of the industry. He will be extremely helpful to us as we move forward with commercialization of our portfolio of diagnostic products including FS069."

Molecular Biosystems Inc., based in San Diego, is a world leader in the development of ultrasound contrast agents for medical imaging. ALBUNEX, the first FDA approved ultrasound imaging agent, is currently marketed in the United States by Mallinckrodt Medical Inc. (Mallinckrodt Group Inc., NYSE:MKG).

CONTACT: Molecular Biosystems Inc., San Diego

Gerard A. Wills/Stephen F. Keane, 619/824-2212